Skip to main
  1. Stocks
  2. Chemed
  3. Forecast
CHE

Chemed (CHE) Stock Forecast & Price Target

Chemed (CHE) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Chemed is attractive because 3Q26 showed both revenue and earnings momentum, with consolidated EBITDA and adjusted EPS ahead of estimates and share performance reflecting confidence in execution. VITAS remains the core driver, as revenue rose 12.2% to $457.4MM, ADC grew 9.4%, and adjusted EBITDA margin expanded to 20.2% ex-Medicare cap, while a $34MM Florida cap cushion and no anticipated FY27 cap liability reduce risk. Roto-Rooter is still pressured by higher marketing costs, but 7.5% revenue growth, improving water-restoration metrics, and management’s expectation that FY26 EPS can meet or exceed $25.75 support a constructive outlook on longer-term earnings power.

Bears say

Chemed is facing a negative fundamental setup because over 90% of VITAS revenue depends on Medicare and Medicaid, leaving earnings vulnerable to reimbursement pressure, Medicare cap risk, and heightened regulatory scrutiny in a highly investigated industry. On the Roto-Rooter side, softer consumer demand in 2027, persistent marketing pressure, and a higher mix of paid leads are likely to weigh on margins, while weaker discretionary plumbing demand could further slow results during an economic downturn. The company’s recent $96M in franchise reacquisitions, including $62.5M in California, also carries integration and ramp risk, with management expecting California to generate only $30-$35M of revenue and less than $4M of EBITDA in 2027.

Chemed (CHE) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Chemed and is not a guaranteed prediction by Public.com or investment advice.

Chemed (CHE) Analyst Forecast & Price Prediction

Get the latest Chemed (CHE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Chemed (CHE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Chemed (CHE) Forecast

Analysts have given Chemed (CHE) a Buy based on their latest research and market trends.

According to 5 analysts, Chemed (CHE) has a Buy consensus rating as of Nov 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $603, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $603, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Chemed (CHE)


Chemed (CHE) Analyst Forecast & Price Prediction

Get the latest Chemed (CHE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Chemed (CHE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CHE stock data and trends